Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








GRADE Evidence Tables – Recommendations in MMWR						Print
																Related Pages
										The following summarize GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods and evidence tables that accompany ACIP recommendations published in the *Morbidity and Mortality Weekly Reports* (MMWR).
This standardized and more explicit process for developing ACIP recommendations is expected to enhance transparency, consistency, and communication.
List of GRADE Materials and Evidence Tables
Listed in most recently published order.
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Tick-Borne Encephalitis (TBE) VaccineLinked from MMWR; November 10, 2023 / 72(5);1–29
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2023-2024 Formulation) | CDCLinked from MMWR; October 20, 2023 / 72(42);1140-1146
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer Maternal RSV Vaccine | CDCLinked from MMWR; October 13, 2023 / 72(41);1115–1122
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged 2 through 18 years with underlying medical conditionsLinked from MMWR; September 29, 2023 / 72(39);1072
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 yearsLinked from MMWR; September 29, 2023 / 72(39);1072
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged 19–64 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)Linked from MMWR; September 8, 2023 / 72(3);1–39
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged ≥65 years who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)Linked from MMWR; September 8, 2023 / 72(3);1–39
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 1Linked from MMWR; August 25, 2023 / 72(34);920–925
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 2Linked from MMWR; August 25, 2023 / 72(34);920–925
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Safety of Influenza Vaccines for Persons with Egg AllergyLinked from MMWR; August 25, 2023 / 72(2);1–25
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY)Linked from MMWR; July 21, 2023 / 72(29);793–801
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO)Linked from MMWR; July 21, 2023 / 72(29);793–801
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Lyophilized CVD 103-HgR Vaccine Among Children and Adolescents Aged 2–17 YearsLinked from MMWR; September 30, 2022 / 71(2);1–8
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged <2 yearsLinked from MMWR; September 16, 2022 / 71(37);1174–1181
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): PCV15 use in children aged 2–18 years with certain underlying medical conditions that increase the risk of pneumococcal diseaseLinked from MMWR; September 16, 2022 / 71(37);1174–1181
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged ≥65 YearsLinked from MMWR; August 26, 2022 / 71(1);1–28
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Novavax COVID-19 Vaccine (cdc.gov)Linked from MMWR; August 4, 2022/ 71(31); 988-992
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6–11 Years
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Persons Aged 12-17 Years
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6 Months–5 YearsLinked from MMWR; June 28, 2022/ 71(26)
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 YearsLinked from MMWR; June 28, 2022/ 71(26)
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS® (orthopoxvirus) vaccine heterologous for those who received ACAM2000 primary seriesLinked from MMWR; June 3, 2022 / 71(22);734–742
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS (orthopoxvirus) vaccine primary series for research, clinical laboratory, response team, and healthcare personnel (Policy Questions 1 and 2)Linked from MMWR; June 3, 2022 / 71(22);734–742
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS® (orthopoxvirus) vaccine booster (Policy Questions 3 and 4)Linked from MMWR; June 3, 2022 / 71(22);734–742
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 2-dose Rabies Vaccination ScheduleLinked from MMWR; May 6, 2022 / 71(18);619–627
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Booster Dose of Rabies VaccineLinked from MMWR; May 6, 2022 / 71(18);619–627
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Hepatitis B (HepB) VaccineLinked from MMWR; April 1, 2022 / 71(13);477–483
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): PreHevbrio Hepatitis B (HepB) VaccineLinked from MMWR; April 1, 2022 / 71(13);477–483
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 VaccineLinked from MMWR; March 18, 2022 / 71(11);416–421
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged 19–64 years with underlying medical conditions or other risk factorsLinked from MMWR; January 28, 2022 / 71(4);109–117
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 yearsLinked from MMWR; January 28, 2022 / 71(4);109–117
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE):15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal conjugate vaccine (PPSV23) for adults aged 19–64 years with underlying medical conditions or other risk factorsLinked from MMWR; January 28, 2022 / 71(4);109–117
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal conjugate vaccine (PPSV23) for adults aged ≥65 yearsLinked from MMWR; January 28, 2022 / 71(4);109–117
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 YearsLinked from MMWR; January 21, 2022 / 71(3);80–84
GRADE Analysis: Dengvaxia® Dengue VaccineLinked from MMWR; December 17, 2021 / 70(6);1–16
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Children 5-11 YearsNovember 5, 2021
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster dosesLinked from MMWR; October 29, 2021 / 70(44)
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 YearsMay 14, 2021
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 VaccineLinked from MMWR; March 2, 2021 / 70(9);329–332
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): rVSVΔG-ZEBOV-GP Ebola vaccine for persons in the U.S. population who are at potential occupational risk of exposure to Ebola virusLinked from MMWR; January 8, 2021 / 70(1);1–12
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 VaccineLinked from MMWR; January 1, 2021 / 69(5152);1653-1656
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 VaccineLinked from MMWR; December 18, 2020 / 69(50);1922-1924
Use of MenACWY-TT (MenQuadfi) as an option for meningococcal serogroup A, C, W, and Y (MenACWY) vaccinationLinked from MMWR; September 25, 2020 / 69(9);1–41
Use of Serogroup B Meningococcal (MenB) vaccines for persons at increased risk for serogroup B meningococcal diseaseLinked from MMWR; September 25, 2020 / 69(9);1–41
Use of Hepatitis A Vaccine for Persons With HIVLinked from MMWR; July 3, 2020 / 69(5);1–38
Use of PCV13 among adults ≥65 years oldLinked from MMWR; November 22, 2019 / 68(46)
Use of HPV Vaccine in Adults, Ages 27 through 45 yearsLinked from MMWR; August 16, 2019 / 68(32);698-702
Use of Japanese Encephalitis VaccineLinked from MMWR; July 19, 2019 / 68(2);1–33
Use of Hepatitis A Vaccine for Persons Experiencing HomelessnessLinked from MMWR; February 15, 2019 / 68(6);153-6
Use of Hepatitis A vaccine for post-exposure prophylaxis in adults >40 years of ageLinked from MMWR; November 1, 2018 / 67(43);1216-1220
Use of Heplisav-B (HepB-CpG)Linked from MMWR; April 20, 2018 / 67(15);455–458
Use of Recombinant Zoster Vaccine (RZV) and Herpes Zoster Live-Attenuated Vaccine (ZVL)Linked from MMWR; January 26, 2018 / 67(3);103-8
Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps Disease Because of a Mumps OutbreakLinked from MMWR; January 12, 2018 / 67(1);33–8
Use of Cholera Lyophilized CVD 103-HgR VaccineLinked from MMWR; May 12, 2017 / 66(18);482-5
Use of a 2-Dose Schedule for Human Papillomavirus VaccinationLinked from MMWR; December 16, 2016 / 65(49);1405-8
Use of Meningococcal Conjugate Vaccines in HIV-Infected PersonsLinked from MMWR; November 4, 2016 / 65(43);1189-94
Use of Smallpox Vaccine in Laboratory and Health-Care Personnel at Risk for Occupational Exposure to OrthopoxvirusesLinked from MMWR; March 18, 2016 / 65(10);257-62
Use of Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults (Including College Students)Linked from MMWR; October 23, 2015 / 64(41);1171-6
Use of Yellow Fever Vaccine Booster DosesLinked from MMWR; June 19, 2015 / 64(23);647-650
Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal DiseaseLinked from MMWR; June 12, 2015 / 64(22);608-612
Use of 9-Valent Human Papillomavirus Vaccine (9vHPV) in Females and MalesLinked from MMWR; March 27, 2015 / 64(11);300-304
Use of Pneumococcal Vaccines for Adults aged ≥65 yearsLinked from MMWR; September 19, 2014 / 63(37);822-815
Use of LAIV in children aged 2 through 8 yearsLinked from MMWR; August 15, 2014 / 63(32);691-697
Use of Japanese Encephalitis Vaccine in ChildrenLinked from MMWR; November 15, 2013 / 62(45);898-900
Pneumococcal Vaccines for Immunocompromised ChildrenLinked from MMWR; June 28, 2013 / 62(25);521-524
Infant Meningococcal VaccinesLinked from MMWR; March 22, 2013 / 62(RR02);1-22
Pneumococcal Vaccines for Immunocompromised AdultsLinked from MMWR; October 12, 2012 / 61(40);816-819
Quadrivalent HPV Vaccine for MalesLinked from MMWR; December 23, 2011 / 60(50);1705-8
Hepatitis B Vaccine in Adults with DiabetesLinked from MMWR; December 23, 2011 / 60(50);1709-11
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged 2 through 18 years with underlying medical conditionsLinked from MMWR; September 29, 2023 / 72(39);1072
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 yearsLinked from MMWR; September 29, 2023 / 72(39);1072
							
					
							Last Reviewed:  November 3, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue